I am a
Home I AM A Search Login

Papers of the Week

2019 Oct

Future Oncol



Final results of a prospective study of scalp cooling in preventing chemotherapy-induced alopecia.


Orlando L, Loparco D, Fedele P, Schiavone P, Quaranta A, Caliolo C, Cinefra M, Rizzo P, Calvani N, Morleo A, Varriano R, Bonuso V, Falcone L L, Caloro M, Cinieri S
Future Oncol. 2019 Oct; 15(29):3337-3344.
PMID: 31578891.


Alopecia is a distressing effect of cancer treatments. Our study examined efficacy and safety of scalp cooling to prevent chemotherapy-induced alopecia. Early breast cancer patients candidate to anthracycline and/or taxane were eligible. Dean's alopecia scale was used to classify alopecia. From February 2016 to November 2018, 127 women were enrolled; 55 (43.3%) received epirubicin/cyclophosphamide (4 EC 3 weeks) followed by paclitaxel (12 P weeks); 50 (39.4%) received 4 EC 3 weeks; 20 (15.7%) received 12 P weeks/trastuzumab and 2 docetaxel/cyclophosphamide (4 TC 3 weeks). The success rate was 71.7% (G0 21.3%, G1 31.5%, G2 18.9%). Frequent side effects were: coldness, headache, scalp pain and head heaviness. In our study, scalp cooling can prevent alopecia thus supporting the wider use in early breast cancer.